Canada Markets closed
  • S&P/TSX

    19,062.91
    +345.79 (+1.85%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • DOW

    31,500.68
    +823.32 (+2.68%)
     
  • CAD/USD

    0.7759
    +0.0064 (+0.8271%)
     
  • CRUDE OIL

    107.06
    +2.79 (+2.68%)
     
  • BTC-CAD

    27,588.07
    +312.95 (+1.15%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • GOLD FUTURES

    1,828.10
    -1.70 (-0.09%)
     
  • RUSSELL 2000

    1,765.74
    +54.06 (+3.16%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • NASDAQ

    11,607.62
    +375.43 (+3.34%)
     
  • VOLATILITY

    27.23
    -1.82 (-6.27%)
     
  • FTSE

    7,208.81
    +188.36 (+2.68%)
     
  • NIKKEI 225

    26,491.97
    +320.72 (+1.23%)
     
  • CAD/EUR

    0.7347
    +0.0040 (+0.55%)
     

MYND Life Sciences Inc. Announces the Recruitment of a Senior Operations and Research Manager

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or "the Company") announces the hiring of a Senior Operations and Research Manager and the resignation of a company officer.

MYND is pleased to announce the hiring of Dr. Chaahat S.B Singh as the Company's Senior Operations and Research Manager. In 2019, Dr. Singh was awarded a PhD in Medical Genetics focusing on Central Nervous System (CNS) disorders at the University of British Columbia. She has previously worked at Panacea Biotec Ltd. on the development of a Hepatitis B vaccine. Later Dr. Singh worked at the Institute of Microbial Technology, India, investigating the mechanisms underlying Drug-resistance in Tuberculosis. During her PhD, under the supervision of MYND's Chief Science Officer, Dr. Wilf Jefferies, Dr. Singh studied vascular dysfunction associated with Alzheimer's disease (AD), establishing an alternative mechanism to explain the blood-brain barrier disruption and disease pathology. Most recently, Dr. Singh co-authored the eBioMedicine-The Lancet publication entitled "Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics," where Dr. Singh and colleagues explored the potential of anti-angiogenic small molecules used in cancer therapy as novel and promising therapeutics for AD.

Chief Science Officer, Dr. Wilf Jefferies, stated that, "Dr. Singh's skills are in organizing and managing complex research and development projects and her scientific experience and extensive research capabilities will be extremely valuable to fulfilling the immense promise of the innovations being developed at MYND".

DEPARTURE OF AN OFFICER OF THE COMPANY

The Company's Board of Directors has accepted the resignation of Chief Financial Officer Mr. Paul Cuillo, with effect from February 28, 2022. The Board would like to express its appreciation to Mr. Cuillo for his efforts, contributions and support with the transition.

Mr. Cuillo's responsibilities will be assumed by our current Senior Controller, and interim Chief Financial Officer, Mr. Lih-Ming Tam. Mr. Tam has worked directly with Mr. Cuillo since MYND's inception. Over the past 30 years, Mr. Tam has established a proven track record in start-up enterprises and established public corporations as a sophisticated financial expert. Mr. Tam is the Chief Financial Officer and Co-Founder of Green Light Innovation Partners and specializes in providing technical, compliance and project funding, management and oversight for Scientific Research and Experimental Development (SRED) programs. Mr. Tam's financial experience and diverse capabilities will undoubtedly assist in advancing MYND's growth.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for the applications of Psilocybins for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.

For more information and to subscribe to MYND's mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION

Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/116073

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting